Lung Cancer Test Kit

[Purpose] KRAS somatic mutations are present in approximately 30% of a variety of cancer patients, including 30-40% in colorectal cancer, 2-10% in non-small cell lung cancer, and 90% in pancreatic cancer. Additionally, 90% of all mutations are concentrated on the 12 and 13 codons in exon.

2. The following is required:It is crucial to note that cancer patients with KRAS mutations do not respond favorably to tyrosine kinase inhibitor therapy, including Iressa, Tarceva, Erbitux, and Vectibix. This suggests that the mutation status should be considered when selecting a therapy. input:
output:This kit identifies seven prevalent mutations in exon 2 of the KRAS gene with a total frequency exceeding 90% (Table 1). input:
output:The kits can be employed for the following purposes: 1) early screening and early diagnosis of cancer, 2) early monitoring of cancer relapse, and 3) the selection of targeted therapy. input:
output:[Principle of detection] This kit employs pyrophosphorolysis-activated polymerization (PAP) technology to selectively amplify mutant DNA, while excluding wildtype DNA molecules. The real-time fluorescence format is used to measure the amplified product. input:
output:[Samples] Plasma, urine, paraffin-embedded tissues, and fresh and frozen tissues. input:
output:[Benefits]

1. High sensitivity: the capacity to identify a single copy of KRAS mutations.

2. High specificity: there are almost no false positive amplifications, even in the presence of a high background of wildtype DNA.

3. The freeze-dried format is a more user-friendly and earlier method of manipulation.

4. Non-invasive sampling: plasma and urine samples may be implemented.